What does CELL-CELL BIO do?

CELL-CELL BIO is a research organisation in Gent. Public Limited, started on 25 February 2022, 1 establishment.

What is the address of CELL-CELL BIO?

The registered office of CELL-CELL BIO is located at Rijvisschestraat 120, 9052 Gent.

Is CELL-CELL BIO still active?

Yes. According to the CBE (29 October 2026) CELL-CELL BIO is active, legal situation “Normale toestand”, started on 25 February 2022.

Is CELL-CELL BIO registered on Peppol?

Yes, CELL-CELL BIO is registered on the Peppol network with ID 0208:0782638362.

What is the enterprise number of CELL-CELL BIO?

The enterprise number of CELL-CELL BIO is BE0782638362.

When was CELL-CELL BIO founded?

CELL-CELL BIO was founded on 25 February 2022.

Who are the directors of CELL-CELL BIO?

According to the 2025 annual accounts, the directors of CELL-CELL BIO are: Doing Well By Doing Good SA, MARA BV.

Is CELL-CELL BIO a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 25 February 2022; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did CELL-CELL BIO make in 2025?

CELL-CELL BIO posted a profit after taxes of € 133,451 in financial year 2025.

What is the revenue of CELL-CELL BIO?

As a small company, CELL-CELL BIO is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 777,487.

CELL-CELL BIO (Public Limited) - Gent - BE0782638362

Dossier CELL-CELL BIO, printed on 29 October 2026 from databakkes.be/en/0782638362/cell-cell-bio. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 27 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

CELL-CELL BIO from Gent, company number BE0782638362, closed financial year 2025 with a result of € 133,451 after tax. For that financial year CELL-CELL BIO recorded a gross margin of € 777,487 and equity of € 588,405. Compared with financial year 2024, the result moved from € 22,073 to € 133,451. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.

What it is worth Growing

€ 588,405

▲ 29% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 133,451

▲ € 111,377 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 3,437

▼ 97% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 88,405.

People and assets in 2025

Wage cost

€ 406,087

▲ 65% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

€ 110,000

▼ 45% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 5,156

▼ 65% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 53,281

▲ 139% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -35,585 Gross margin 2022: € -35,585 First fiscal year in the series	€ 226,629 Gross margin 2023: € 226,629 ▲ € 262,213 vs 2022 (€ -35,585) Favourable step	€ 454,550 Gross margin 2024: € 454,550 ▲ 101% vs 2023 (€ 226,629) Favourable step	€ 777,487 Gross margin 2025: € 777,487 ▲ 71% vs 2024 (€ 454,550) Favourable step	▲ 71%
Profit after taxes	€ -83,620 Profit after taxes 2022: € -83,620 First fiscal year in the series	€ 16,501 Profit after taxes 2023: € 16,501 ▲ € 100,121 vs 2022 (€ -83,620) Favourable step	€ 22,073 Profit after taxes 2024: € 22,073 ▲ 34% vs 2023 (€ 16,501) Favourable step	€ 133,451 Profit after taxes 2025: € 133,451 ▲ € 111,377 vs 2024 (€ 22,073) Favourable step	▲ € 111,377
Equity	€ 416,380 Equity 2022: € 416,380 First fiscal year in the series	€ 432,881 Equity 2023: € 432,881 ▲ 4% vs 2022 (€ 416,380) Favourable step	€ 454,955 Equity 2024: € 454,955 ▲ 5% vs 2023 (€ 432,881) Favourable step	€ 588,405 Equity 2025: € 588,405 ▲ 29% vs 2024 (€ 454,955) Favourable step	▲ 29%
Total debts	€ 83,583 Total debts 2022: € 83,583 First fiscal year in the series	€ 39,029 Total debts 2023: € 39,029 ▼ 53% vs 2022 (€ 83,583) Favourable step	€ 237,157 Total debts 2024: € 237,157 ▲ € 198,127 vs 2023 (€ 39,029) Unfavourable step	€ 402,166 Total debts 2025: € 402,166 ▲ 70% vs 2024 (€ 237,157) Unfavourable step	▲ 70%
Cash	€ 272,202 Cash 2022: € 272,202 First fiscal year in the series	€ 80,943 Cash 2023: € 80,943 ▼ 70% vs 2022 (€ 272,202) Unfavourable step	€ 104,618 Cash 2024: € 104,618 ▲ 29% vs 2023 (€ 80,943) Favourable step	€ 3,437 Cash 2025: € 3,437 ▼ 97% vs 2024 (€ 104,618) Unfavourable step	▼ 97%
Retained profit	€ -83,620 Retained profit 2022: € -83,620 First fiscal year in the series	€ -67,119 Retained profit 2023: € -67,119 ▲ € 16,501 vs 2022 (€ -83,620) Favourable step	€ -45,045 Retained profit 2024: € -45,045 ▲ € 22,073 vs 2023 (€ -67,119) Favourable step	€ 88,405 Retained profit 2025: € 88,405 ▲ € 133,451 vs 2024 (€ -45,045) Favourable step	▲ € 133,451
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 200,000 Bank debt 2024: € 200,000 Unchanged (€ 0) Unfavourable step	€ 110,000 Bank debt 2025: € 110,000 ▼ 45% vs 2024 (€ 200,000) Favourable step	▼ 45%
Balance sheet total	€ 499,963 Balance sheet total 2022: € 499,963 First fiscal year in the series	€ 471,911 Balance sheet total 2023: € 471,911 ▼ 6% vs 2022 (€ 499,963) Unchanged	€ 692,111 Balance sheet total 2024: € 692,111 ▲ 47% vs 2023 (€ 471,911) Unchanged	€ 990,571 Balance sheet total 2025: € 990,571 ▲ 43% vs 2024 (€ 692,111) Unchanged	▲ 43%

Key figures of CELL-CELL BIO, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CELL-CELL BIO?

What happened at CELL-CELL BIO in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2030 MARA BV stepped down as director. NBB
2028 Doing Well By Doing Good SA stepped down as director. NBB
Aug 28, 2026 New annual accounts for financial year 2025: profit of € 133,451 (▲ € 111,377 vs 2024). filed late Source: NBB ↗
2025 MARA BV became a director. NBB
Feb 25, 2022 New establishment in Gent. KBO
2022 Doing Well By Doing Good SA became a director. NBB
Feb 25, 2022 Start of the company according to the CBE. KBO

In short

From € 83,620 loss in 2022 to € 133,451 profit in 2025.

Paid € 710 in corporate taxes since 2022.

Best year ever: 2025, with € 133,451 profit.

Original PDFs at the National Bank ↗

Management

Directors

According to the 2025 annual accounts

Doing Well By Doing Good SA

Director · represented by Christiaan Cardon

Also active at: DOING WELL BY DOING GOOD, Puxano, CARDON BIO, BELLEVUE

since 2022 · until 2028

MARA BV

Director · represented by Hendrik Thys

Also active at: Puxano, CARDON BIO

since 2025 · until 2030

Establishments

Establishment units

Physical locations of this company

Registered office

Rijvisschestraat 120

9052 Gent

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.

All companies at this address →

RNA Pioneering

€ -111,461 gross margin · 2025

DOING WELL BY DOING GOOD same network

€ 27,550 gross margin · 2025

Ziphius

€ 2.4 million gross margin · 2025

CARDON BIO same network

€ 25,626 gross margin · 2025

BORDEAUX I

€ -3,685 gross margin · 2025

+1 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0782.638.362

VAT number

BE 0782.638.362

Registered office

Rijvisschestraat 120, 9052 Gent

Names & denominations

CELL-CELL BIO

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

25 February 2022

Peppol

Active · Active since 24 Nov 2023

Activities · NACE

Speur- en ontwikkelingswerk op biotechnologisch gebied

Activiteiten van medische beeldvorming en medische laboratoria

Activiteiten van medische laboratoria

Handelsbemiddeling in de groothandel in andere specifieke goederen

Vervaardiging van overige farmaceutische producten

Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Vervaardiging van geneesmiddelen

Vervaardiging van farmaceutische grondstoffen

View on CBE Public ↗ Annual accounts (NBB) ↗